

This listing of claims will replace all prior versions of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Withdrawn) A polynucleotide whose sequence is set forth in SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5.

Claim 2. (Withdrawn) The polynucleotide according to Claim 1, commencing with position 70, which encodes for a polypeptide having the properties of the major allergen Phl p 4 from *Phleum pratense*.

Claim 3. (Withdrawn) A polynucleotide comprising a nucleotide sequence which encodes for the major allergen Phl p 4 from *Phleum pratense*.

Claim 4. (Withdrawn) A DNA molecule which hybridizes with the polynucleotide sequence according to claim 1 under stringent conditions and originates from DNA sequences of *Poaceae* species.

Claim 5. (Withdrawn) A DNA molecule which encodes for a polypeptide which cross-reacts immunologically with the major allergen Phl p 4 from *Phleum pratense* and originates from DNA sequences of *Poaceae* species.

Claim 6. (Withdrawn) A DNA molecule corresponding to a partial sequence or a combination of partial sequences according to claim 1 which encodes for an immunomodulatory, T-cell-reactive fragment of a group 4 *Poaceae* allergen.

Claim 7. (Withdrawn) The DNA molecule according to Claim 6, which encodes for a Phl p 4 fragment which is

- (a) fragment 1-200, with amino acids 1-200 of Phl p 4, or
- (b) fragment 185-500, with amino acids 185-500 of Phl p 4.

Claim 8. (Withdrawn) The polynucleotide sequence according to claim 1, which encodes for an immunomodulatory T-cell-reactive fragment, wherein said nucleotide sequence has been specifically modified by specific mutation of individual codons, elimination or addition.

Claim 9. (Withdrawn) The polynucleotide according to Claim 8, wherein said mutation results in the replacement of one, more or all cysteines of the corresponding polypeptide with another amino acid.

Claim 10. (Withdrawn) A recombinant DNA expression vector or a cloning system comprising the polynucleotide according to claim 1, functionally linked to an expression control sequence.

Claim 11. (Withdrawn) A transformed host organism which expresses the polypeptide according to claim 13.

Claim 12. (Withdrawn) A process for the preparation of a polypeptide of claim 13 comprising culturing a host organism which expresses said polypeptide and isolating the corresponding polypeptide from the culture.

Claim 13. (Currently Amended) A polypeptide which is comprises

- (a) a polypeptide whose which comprises the polypeptide sequence is set forth in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6,
- (b) ~~a polypeptide comprising a mutation, elimination or addition of at least one amino acid residue in the polypeptide sequence set forth in (a);~~
- (e) a polypeptide comprising a polypeptide sequence which is encoded by a the polynucleotide whose sequence is set forth in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, or
- (d) (c) a variant polypeptide which comprises at least 90.8% sequence identity to the polypeptide sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 is encoded by a polynucleotide sequence which hybridizes to the complement of the polynucleotide sequences in (e) under stringent conditions and originates from DNA sequences of *Poaceae* species

- (e) ~~(d)~~ a polypeptide which comprises at least 79.9% sequence identity to the polypeptide comprising amino acids 219 to 362 of the polypeptide sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 is encoded by a single nucleotide polymorph of the polynucleotide sequence set forth in (e),
- (e) a polypeptide which comprises at least 69.7% sequence identity to the polypeptide comprising amino acids 219 to 251 of the polypeptide sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6

wherein each of the polypeptides of (a) to (e) is immunogenic and induces an immunomodulatory T-cell reactive response in a host.

Claim 14. (Cancelled)

Claim 15. (Previously Presented) A pharmaceutical composition comprising at least one polypeptide according to Claim 13 and a pharmaceutically acceptable carrier.

Claim 16. (Withdrawn) A method for the diagnosis and/or treatment of an allergic condition which is triggered by group 4 allergens of the *Poaceae* and/or for the prevention of said allergic condition in a subject in need thereof comprising administering to said subject an effective amount of a polypeptide of claim 13.

Claim 17. (Cancelled)

Claim 18. (Cancelled)

Claim 19. (Cancelled)

Claim 20. (Currently Amended) An immunotherapeutic ~~vaccine~~ vaccine comprising a polypeptide of claim 13 and an acceptable carrier, wherein said vaccine is capable of generating an immunomodulatory, T-cell response in a host.

Claim 21. (Currently Amended) An immunomodulatory, T-cell-reactive polypeptide fragment of a group 4 *Poaceae* allergen which comprises a partial sequence of 50 to 350 amino acids ~~or a combination of partial sequences~~ of at least one polypeptide of claim 13.

Claim 22. (Currently Amended) The An immunomodulatory, T-cell-reactive polypeptide fragment of a group 4 *Poaceae* allergen according to ~~claim 21~~ which comprises is

- (a) fragment 1-200, with amino acids 1-200 of the polypeptide of claim 13 Phl-p-4, or
- (b) fragment 185-500, with amino acids 185-500 of the polypeptide of claim 13 Phl-p-4.

Claim 23. (Currently Amended) The variant polypeptide according to Claim 13 ~~(b)~~ (c) which comprises a mutation, wherein said mutation results in the replacement of at least one cysteine residue of a polypeptide whose sequence is set forth in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6 with another amino acid residue.

Claim 24. (Cancelled)

Claim 25. (Currently Amended) An immunotherapeutic vaccine comprising a polypeptide of claim 14 13 and an acceptable carrier, wherein said vaccine is capable of generating an immunomodulatory, T-cell response in a host.

Claim 26. (New) A polypeptide according to claim 13 wherein each of the polypeptides of (a) to (e) is immunogenic and induces an immunomodulatory T-cell reactive response in a host.

Claim 27. (New) An immunotherapeutic vaccine comprising a polypeptide of claim 21 and an acceptable carrier, wherein said vaccine is capable of generating an immunomodulatory, T-cell response in a host.

Claim 28. (New) An immunotherapeutic vaccine comprising a polypeptide of claim 22 and an acceptable carrier, wherein said vaccine is capable of generating an immunomodulatory, T-cell response in a host.

Claim 29. (New) An immunotherapeutic vaccine comprising a polypeptide of claim 23 and an acceptable carrier, wherein said vaccine is capable of generating an immunomodulatory, T-cell response in a host.

Claim 30. (New) A pharmaceutical composition comprising at least one polypeptide according to claim 21 and a pharmaceutically acceptable carrier.

Claim 31. (New) A pharmaceutical composition comprising at least one polypeptide according to claim 22 and a pharmaceutically acceptable carrier.

Claim 32. (New) A pharmaceutical composition comprising at least one polypeptide according to claim 23 and a pharmaceutically acceptable carrier.

Claim 33. (New) A polypeptide which comprises

- (a) a polypeptide which is encoded by single nucleotide polymorph of a polynucleotide whose sequence is set forth in SEQ ID NO: 1,
- (b) a single amino acid polymorph of a polypeptide whose sequence is set forth in SEQ ID NO: 2,

Claim 34. (New) A polypeptide which comprises a polypeptide variant of the sequence set forth in SEQ ID NO: 2 with the amino acid variations set forth clones 1 to 11:

- (a) clone 1: L54, I57, V62, S76, T100, N107, Y137, P141, T142, K189, Q219, K221, L227, I231, 5235, T237, V238, K248, A258, I264, K270, K282, L287, P299, A321, L322, S332, Q346, P347, T351, L357, N358, V362, S384, A410, D419, Y456, A457, K460, E472;
- (b) clone 2: L54, I57, V62, T76, T100, N107, Y137, P141, T142, K189, Q219, K221, I231, S235, T237, V238, K248, A258, I264, K270, K282, L287, P299, A321, L322, S332, Q346, P347, T351, L357, N358, V362, S384, A410, D419, Y456, A457, K460, E472;
- (c) clone 3: P141, K282, L287, P299, L347, E351;
- (d) clone 4: G289, A410, D419, Y456, A457, K460, E472;
- (e) clone 5: L347, E351, S384, A410, D419, Y456, A457, K460, E472;
- (f) clone 6: N107, Y137, P141, T142, K189, Q219, K221, I231, S235, T237, V238, K248, A258, I264, K270, K282, L287, P299, A321, L322, S332, Q346, P347, T351, L357, N358, V362, S384, A410, D419, Y456, A457, K460;
- (g) clone 7: K248, A258, I264, K270, K282, L287, P299, A321, L322, S332, Q346, P347, T351, L357, N358, V362, S384;

- (h) clone 8: Q219, K221, I231, S235, T237, V238, K248, A258, I264, K270, K282, L287, P299, E351;
- (i) clone 9: M231, T246, A251, C263, G289, L307, L309, E334;
- (j) clone 10: Q219, K221, I231, S235, T237, M238, V242, V246, K248, A258, I264, K270, K282, L287, P299, A321, L322, S332, Q346, P347, T351, N358, V362, S384, insertion of GA between positions 407 and 408, N452, Y456, A457, K460, E472;
- (k) clone 11: insertion of GA between positions 407 and 408.